Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea · Delayed Price · Currency is KRW 32,900
-1,000 (-2.95%)
Last updated: Sep 9, 2025, 9:33 AM KST
Hanall Biopharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 150,089 | 138,944 | 134,910 | 109,995 | 101,594 | 88,602 | Upgrade |
Other Revenue | - | - | -0 | -0 | -0 | - | Upgrade |
| 150,089 | 138,944 | 134,910 | 109,995 | 101,594 | 88,602 | Upgrade | |
Revenue Growth (YoY) | 15.12% | 2.99% | 22.65% | 8.27% | 14.66% | -18.30% | Upgrade |
Cost of Revenue | 70,231 | 65,738 | 59,870 | 48,120 | 41,364 | 38,027 | Upgrade |
Gross Profit | 79,858 | 73,206 | 75,040 | 61,876 | 60,231 | 50,575 | Upgrade |
Selling, General & Admin | 55,322 | 51,850 | 47,520 | 42,586 | 38,472 | 34,264 | Upgrade |
Research & Development | 19,302 | 19,993 | 23,945 | 16,498 | 10,462 | 9,316 | Upgrade |
Other Operating Expenses | 672.89 | 660.34 | 669.45 | 584.09 | 605.75 | 541.03 | Upgrade |
Operating Expenses | 75,938 | 72,975 | 73,296 | 60,370 | 50,132 | 44,640 | Upgrade |
Operating Income | 3,920 | 230.47 | 1,743 | 1,506 | 10,099 | 5,935 | Upgrade |
Interest Expense | -78.34 | -70.97 | -63.86 | -21.88 | -25.48 | -16.01 | Upgrade |
Interest & Investment Income | 475.09 | 490.32 | 1,227 | 1,427 | 719.84 | 2,145 | Upgrade |
Earnings From Equity Investments | -95.9 | -99.53 | -62.12 | -45.39 | - | - | Upgrade |
Currency Exchange Gain (Loss) | 5.68 | -408.83 | 349.6 | -600.15 | -115.94 | 82.78 | Upgrade |
Other Non Operating Income (Expenses) | -468.86 | -203.55 | -1,067 | -228.48 | -745.87 | 11,138 | Upgrade |
EBT Excluding Unusual Items | 3,758 | -62.07 | 2,127 | 2,037 | 9,932 | 19,284 | Upgrade |
Gain (Loss) on Sale of Investments | 52.32 | 331.43 | 1,121 | -124.34 | -177.44 | - | Upgrade |
Gain (Loss) on Sale of Assets | -229.61 | -452.56 | -9.32 | 16.99 | -1,052 | -14.29 | Upgrade |
Asset Writedown | - | - | -36.72 | - | - | -44.82 | Upgrade |
Pretax Income | 3,581 | -183.2 | 3,203 | 1,929 | 8,702 | 19,225 | Upgrade |
Income Tax Expense | 1,347 | 1,622 | -306.08 | 1,678 | -194.05 | -539.21 | Upgrade |
Net Income | 2,233 | -1,805 | 3,509 | 251.47 | 8,896 | 19,765 | Upgrade |
Net Income to Common | 2,233 | -1,805 | 3,509 | 251.47 | 8,896 | 19,765 | Upgrade |
Net Income Growth | - | - | 1295.23% | -97.17% | -54.99% | 3.08% | Upgrade |
Shares Outstanding (Basic) | 50 | 51 | 51 | 51 | 51 | 51 | Upgrade |
Shares Outstanding (Diluted) | 50 | 51 | 51 | 51 | 51 | 51 | Upgrade |
Shares Change (YoY) | -1.64% | 0.04% | -0.24% | -0.76% | 0.05% | 0.00% | Upgrade |
EPS (Basic) | 44.81 | -35.59 | 69.21 | 4.95 | 173.74 | 386.19 | Upgrade |
EPS (Diluted) | 44.81 | -35.59 | 69.21 | 4.95 | 173.74 | 386.19 | Upgrade |
EPS Growth | - | - | 1298.63% | -97.15% | -55.01% | 3.08% | Upgrade |
Free Cash Flow | 12,373 | 7,718 | 27,231 | 22,434 | -3,766 | -1,633 | Upgrade |
Free Cash Flow Per Share | 248.25 | 152.20 | 537.18 | 441.48 | -73.55 | -31.91 | Upgrade |
Gross Margin | 53.21% | 52.69% | 55.62% | 56.25% | 59.29% | 57.08% | Upgrade |
Operating Margin | 2.61% | 0.17% | 1.29% | 1.37% | 9.94% | 6.70% | Upgrade |
Profit Margin | 1.49% | -1.30% | 2.60% | 0.23% | 8.76% | 22.31% | Upgrade |
Free Cash Flow Margin | 8.24% | 5.56% | 20.18% | 20.39% | -3.71% | -1.84% | Upgrade |
EBITDA | 7,206 | 3,351 | 4,990 | 4,558 | 12,824 | 8,829 | Upgrade |
EBITDA Margin | 4.80% | 2.41% | 3.70% | 4.14% | 12.62% | 9.96% | Upgrade |
D&A For EBITDA | 3,285 | 3,121 | 3,247 | 3,053 | 2,725 | 2,894 | Upgrade |
EBIT | 3,920 | 230.47 | 1,743 | 1,506 | 10,099 | 5,935 | Upgrade |
EBIT Margin | 2.61% | 0.17% | 1.29% | 1.37% | 9.94% | 6.70% | Upgrade |
Effective Tax Rate | 37.63% | - | - | 86.97% | - | - | Upgrade |
Advertising Expenses | - | 3,230 | 3,287 | 3,090 | 2,112 | 1,889 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.